Deutsch

Innovacell - Biotechnologie

Innovacell_History

History

2013

 

Innovacell and Norgine announce a cooperation and licensing agreement covering ICEF15. This co-operation introduces additional development marketing know-how to the enterprise.

2013

 

Innovacell launches a pharmaco-dynamic study for ICES13 in Slovenia, alongside its Phase III study.

2012

 

Innovacell successfully concludes the second, single-centre Phase I/II study.

2012

 

Ground-breaking findings from the Phase III study of ICES13 allow for a more gentle and simple treatment.

2011

 

 

 

Innovacell successfully concludes the multi-centre Phase IIb study conducted at 32 centres in four European countries and launches a multi-centre Phase III study in six European countries.

2010

 

Innovacell begins the Phase IIb clinical trials for ICES13 in four European countries.

2009

 

Innovacell gets approval from the European health authorities to begin the Phase IIb clinical trials of ICES13. Innovacell installs a cryo-preservation unit. This allows cell cultures to be stored over a longer period without any reduction in quality, to the highest safety standards, thus ready to be shipped and implanted at a time of the patient's own choosing.

2008

 

Innovacell sets its sights on future expansion and becomes a private limited company in private ownership. The first patients are treated within the framework of clinical trials with cell-therapy product ICEF15.

2007

 

The European Patent Office (EPO) grants Innovacell patent protection for Sonoject®, its innovative injection device.

More than 500 patients have already been treated with a precursor product of ICES13. The clinical development of ICES13 begins with the entry into force of EU Edict 1394/2007.

2006

 

Marketing of cell-therapies begins.

2005

 

Innovacell commissions Europe's largest facility for producing autologous cell-therapy treatments.

2002

 

The first patients receive treatment within the framework of clinical studies into cell therapy.

2001

 

Innovacell wins the Tyrolean business plan competition
"Adventure X“.

2000

 

Innovacell Biotechnologie GmbH is founded as a spin-off enterprise of Innsbruck Medical University.